Clinical Trials

1,083 enrolled 29 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

292 enrolled 21 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03246347 2026-01-23

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

40 enrolled 12 charts

Prostatic Neoplasms

NCT03556904 2026-01-15

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

14 enrolled 16 charts

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT06072196 2025-12-31

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

3,017 enrolled 5 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

188 enrolled 25 charts

Prostatic Neoplasms

NCT05457257 2025-12-19

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

43 enrolled 16 charts

Metastatic Castration-resistant Prostate Cancer

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02312557 2025-12-03

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

58 enrolled 13 charts

Prostatic Neoplasms

NCT02203695 2025-10-28

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

86 enrolled 13 charts

Adenocarcinoma of the Prostate

NCT02294461 2025-10-24

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

395 enrolled 25 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02677896 2025-10-24

ARCHES

1,150 enrolled 23 charts 2 FDA

Metastatic Hormone Sensitive Prostate Cancer

NCT03939689 2025-10-14

ARROW

120 enrolled 21 charts

Prostatic Neoplasms

NCT02975934 2025-07-25

TRITON3

405 enrolled 34 charts 3 FDA

Metastatic Castration Resistant Prostate Cancer

NCT03834493 2025-07-18

KEYNOTE-641

1,244 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02430480 2025-07-16

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

39 enrolled 21 charts

Prostatic Neoplasms

NCT02204072 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Phase 1 Completed

120 enrolled 28 charts

Prostatic Neoplasms, Castration-Resistant

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 2 FDA

Prostatic Neoplasms

NCT06151418 2025-06-04

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

2,313 enrolled 5 charts

Prostatic Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03300505 2025-05-13

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Phase 1 Terminated

9 enrolled 14 charts

Prostatic Neoplasms

NCT02278185 2025-05-11

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

19 enrolled 18 charts

Prostatic Neoplasms

NCT02288247 2025-04-08

PRESIDE

688 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03641560 2025-04-08

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

52 enrolled 10 charts

Metastatic Castration Resistant Prostate Cancer

NCT02918968 2024-12-09

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

206 enrolled 16 charts

Prostatic Neoplasms

NCT01288911 2024-12-06

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

375 enrolled 24 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT01534052 2024-12-06

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

52 enrolled 16 charts

Prostatic Neoplasms

NCT02116582 2024-12-06

A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

215 enrolled 11 charts

Metastatic Castration-Resistant Prostate Cancer

NCT02799745 2024-12-06

ENACT

227 enrolled 24 charts

Prostatic Neoplasms

NCT02213107 2024-11-13

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

43 enrolled 10 charts

Prostatic Neoplasms

NCT05520138 2024-09-27

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

5,506 enrolled 11 charts

Prostatic Neoplasms, Castration-Resistant

NCT04207255 2024-09-25

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

69 enrolled 13 charts

Prostatic Neoplasms

NCT02099864 2024-09-19

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

36 enrolled 26 charts

Prostatic Neoplasms

NCT03016312 2024-08-09

IMbassador250

759 enrolled 22 charts

Prostatic Neoplasms, Castration-Resistant

NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Phase 2 Terminated

8 enrolled 7 charts

BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Metastatic Castration-resistant Prostate Cancer

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

49 enrolled 33 charts

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

40 enrolled 18 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

387 enrolled 16 charts 3 FDA

Metastatic Castration-resistant Prostate Cancer

NCT01949337 2023-09-28

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Phase 3 Unknown

1,311 enrolled 12 charts

Prostatic Neoplasms

NCT03999515 2023-09-28

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Phase 2 Terminated

3 enrolled 9 charts

Prostatic Neoplasms

NCT01867333 2023-09-26

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

57 enrolled 14 charts